Xeris Biopharma Holdings, Inc. (XERS) P/E Ratio History
ExpensiveTrading at 2403.1x vs 5Y avg 89.2x · 100th percentile · Material premium to history · Data 2026–2026
Loading P/E history...
P/E Ratio Analysis
As of June 27, 2026, Xeris Biopharma Holdings, Inc. (XERS) trades at a price-to-earnings ratio of 2403.1x, with a stock price of $7.69 and trailing twelve-month earnings per share of $0.07.
The current P/E is 2593% above its 5-year average of 89.2x. Over the past five years, XERS's P/E has ranged from a low of 89.2x to a high of 89.2x, placing the current valuation at the 100th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.0x, XERS trades at a 10338% premium to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.4x.
Relative to the broader market, XERS commands a significant premium over the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our XERS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
XERS Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
XERS P/E vs Peers
Commercial Rare Disease Biopharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $7B | 32.2 | - | -22% | |
| $1B | 26.6 | 3.56 | +1883%Best | |
| $9B | 106.5 | - | -33% | |
| $5B | 78.3 | - | +158% | |
| $213B | 13.7Lowest | 0.66Best | +2% | |
| $1.1T | 52.6 | 1.82 | +96% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
XERS Historical P/E Data (2026–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $5.80 | $0.07 | 89.2x | +0% |
Average P/E for displayed period: 89.2x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10-year return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
XERS — Frequently Asked Questions
Quick answers to the most common questions about buying XERS stock.
What is XERS's P/E ratio?
Xeris Biopharma Holdings, Inc. (XERS) trailing twelve-month P/E ratio is 2403.1x, based on TTM diluted EPS of $0.07. The 5-year average P/E is 89.2x and the historical range spans 89.2x to 89.2x.
Is XERS stock overvalued or undervalued?
XERS trades at 2403.1x P/E, above its 5-year average of 89.2x. The 100th percentile ranking within the 89.2x–89.2x historical range indicates a premium to historical valuation.
Is XERS stock expensive?
Yes, XERS is expensive relative to its own history. The current P/E of 2403.1x is above the 5-year average of 89.2x and also above the Healthcare sector median of 23.0x. The stock sits at the 100th percentile of its 5-year valuation range.
What is XERS's historical P/E range?
Over the past 5 years, XERS's P/E ratio has ranged from 89.2x to 89.2x, with a median of 89.2x and an average of 89.2x. The current P/E of 2403.1x places the stock at the 100th percentile of this range. Full historical data spans 2026–2026.
How does XERS's P/E compare to the S&P 500?
XERS trades at 2403.1x P/E versus the S&P 500 median of 25.3x. The 9398% premium to the market typically reflects higher expected earnings growth or quality.
How does XERS's valuation compare to Healthcare peers?
Xeris Biopharma Holdings, Inc. P/E of 2403.1x compares to the Healthcare sector median of 23.0x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is XERS's PEG ratio?
XERS PEG ratio is N/A, based on a P/E of 2403.1x and EPS growth of 100.9%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is XERS's earnings yield?
XERS earnings yield is 0.04%, the inverse of its 2403.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.